Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ELUT logo ELUT
Upturn stock ratingUpturn stock rating
ELUT logo

Elutia Inc. (ELUT)

Upturn stock ratingUpturn stock rating
$2.33
Last Close (24-hour delay)
Profit since last BUY-2.51%
upturn advisory
Consider higher Upturn Star rating
BUY since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: ELUT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.5

1 Year Target Price $6.5

Analysts Price Target For last 52 week
$6.5 Target price
52w Low $1.61
Current$2.33
52w High $5.12

Analysis of Past Performance

Type Stock
Historic Profit -39.17%
Avg. Invested days 18
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 98.78M USD
Price to earnings Ratio -
1Y Target Price 6.5
Price to earnings Ratio -
1Y Target Price 6.5
Volume (30-day avg) 2
Beta 0.88
52 Weeks Range 1.61 - 5.12
Updated Date 08/29/2025
52 Weeks Range 1.61 - 5.12
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.43

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-14
When -
Estimate -0.19
Actual -0.26

Profitability

Profit Margin -90.01%
Operating Margin (TTM) -93.74%

Management Effectiveness

Return on Assets (TTM) -37.27%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 118522143
Price to Sales(TTM) 4.17
Enterprise Value 118522143
Price to Sales(TTM) 4.17
Enterprise Value to Revenue 5
Enterprise Value to EBITDA -3.32
Shares Outstanding 38081900
Shares Floating 15385269
Shares Outstanding 38081900
Shares Floating 15385269
Percent Insiders 2.2
Percent Institutions 70.65

ai summary icon Upturn AI SWOT

Elutia Inc.

stock logo

Company Overview

overview logo History and Background

Elutia Inc., formerly known as SurModics, Inc., was founded in 1979. It initially focused on surface modification technologies before evolving into a medical device company. It transitioned after selling its In Vitro Diagnostics and SurModics Pharmaceuticals businesses to focus on its Preecludia and Biorez technologies in 2024. The company rebranded as Elutia Inc. to mark its renewed focus.

business area logo Core Business Areas

  • Biorez: BioREZ is a reinforced soft tissue repair technology utilizing a proprietary polymer composite. The Biorez platform utilizes a unique polymer that exhibits superior biointegration when implanted in vivo.
  • Drug Delivery: Elutia's drug delivery technologies are designed to provide sustained and localized drug release to target tissues. These technologies enhance the efficacy and safety of therapeutic agents.
  • Preecludia: Preecludia is a platform technology for anti-thrombotic and anti-inflammatory therapies. It is a key focus for Elutia, aimed at reducing blood clots and inflammation related to medical devices.

leadership logo Leadership and Structure

Elutia Inc.'s leadership team consists of a CEO, CFO, and other key executives overseeing various departments like R&D, marketing, and operations. The organizational structure is hierarchical, with clear lines of reporting and accountability. David A. Dullum is the CEO and President.

Top Products and Market Share

overview logo Key Offerings

  • BioREZ Platform: BioREZ offers a solution for soft tissue repair. Market share data for BioREZ is emerging; revenue attributable to Biorez in Q1 2024 was $1.3 million. Competitors include companies offering collagen scaffolds and other soft tissue repair products, such as Stryker and Smith & Nephew.
  • Preecludia Platform: Preecludia technology is designed to improve the biocompatibility of medical devices to reduce the risk of thrombosis and inflammation. Market share data specific to Preecludia is not readily available. Competitors in anti-thrombotic coating technologies include Medtronic, Abbott, and Boston Scientific.
  • Sustained Drug Delivery: Elutia focuses on drug delivery technologies for various applications including localized drug release for medical devices. Competitors: Durect, Alkermes, and Vectura.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is characterized by continuous innovation, stringent regulatory requirements, and high competition. Key trends include the development of minimally invasive procedures, personalized medicine, and advanced biomaterials.

Positioning

Elutia Inc. is positioned as an innovator in biomaterials and drug delivery, focusing on high-growth areas within the medical device industry. Its competitive advantages include proprietary technologies and a focus on addressing unmet clinical needs.

Total Addressable Market (TAM)

The global medical device market is estimated to reach hundreds of billions of dollars. Elutia Inc.'s focus on specialized areas such as anti-thrombotic coatings and soft tissue repair positions it to capture a portion of this TAM. The TAM for soft tissue repair and anti-thrombotic coatings combined could be in the billions of dollars annually.

Upturn SWOT Analysis

Strengths

  • Proprietary Technology Platforms (Preecludia, BioREZ)
  • Expertise in Biomaterials and Drug Delivery
  • Focus on high-growth medical device segments
  • Strong R&D capabilities
  • Experienced Management Team

Weaknesses

  • Limited commercial infrastructure as a smaller company
  • Dependence on regulatory approvals for new products
  • Cash burn and need for additional financing
  • Revenue concentration from limited products

Opportunities

  • Expansion into new therapeutic areas
  • Strategic partnerships and collaborations
  • Acquisition of complementary technologies
  • Increasing demand for advanced biomaterials
  • Growing market for minimally invasive procedures

Threats

  • Intense competition from larger medical device companies
  • Changing regulatory landscape
  • Product liability risks
  • Economic downturn affecting healthcare spending
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • ABT
  • BSX
  • JNJ

Competitive Landscape

Elutia Inc. faces strong competition from larger, more established medical device companies. Its competitive advantages lie in its proprietary technologies and specialized expertise. However, its limited commercial infrastructure and financial resources pose challenges.

Growth Trajectory and Initiatives

Historical Growth: Elutia's growth has been driven by innovation in biomaterials. Divestiture of businesses, including SurModics Pharmaceuiticals has affected revenue.

Future Projections: Future growth depends on regulatory approvals and successful commercialization of its Preecludia and BioREZ technologies. Analysts forecast increased revenue in the next few years.

Recent Initiatives: Recent strategic initiatives include rebranding, focusing on Preecludia and BioREZ platforms, and optimizing its operations.

Summary

Elutia is a medical device company with specialized biomaterial expertise and proprietary technologies but faces stiff competition from established players and needs additional funding to support operations. Successful commercialization of its BioREZ and Preecludia platforms is critical for future growth. Elutia must manage its cash burn and secure regulatory approvals to succeed. With the right execution, Elutia can become a strong company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (10-K, 10-Q)
  • Earnings call transcripts
  • Press releases
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on publicly available information and analyst estimates. It is not financial advice, and investors should conduct their own due diligence before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Elutia Inc.

Exchange NASDAQ
Headquaters Silver Spring, MD, United States
IPO Launch date 2023-09-07
Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D.
Sector Healthcare
Industry Medical Devices
Full time employees 51
Full time employees 51

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.